Thrombosis in PNH: Prevention and Therapy Florence 04-10-2024

Petra Muus

Disclosures:

Travel support Alexion; Advisory Board/Lecture fees Novartis, Roche and Sobi.

PICO questions and grading the evidence.

- *Population*: Patients with PNH
- *Intervention*: Anticoagulation
- *Comparison*: No anticoagulation
- *Outcome*: Thrombosis

GRADE Grading of Recommendation Assessment, Development and Evaluation

- **High**: very confident true effect close to estimated effect
- Moderate: true effect likely close to estimated effect
- Low: limited confidence that true effect lies close to estimated effect

(Very low: true effect likely substantially different from estimated effect)

04/10/2024


Prevention of thrombosis with

anticoagulation (Vitamin K antagonist, LMWH, DOACS): yes or no?

Yes: if no contra -indication

- If history of PNH relatedthrombosis.
- If granulocyte or monocyte clone >50% .
- In pregnancy even with a moderate clone.





09/09/2024: 17.17% PNH neutrophils, 37.21% PNH monocytes, 0.82% PNH erythrocytes and 17.74% PNH reticulocytes (0.57% type II and 17.27% type III cells).

Prevention: YES: Hall et al, Blood 2003; 102: 3587 – 3591.

Retrospective study: since 1997 warfarin targeting INR 2-3, if gran clone > 50% and plts>100x10.9/L. N=163, med FU 6 yr (0.2 - 38 yrs).

Clone	Patients	On anticoa	agulation	l		
>50%	97		32			
<u><</u> 50% / unknown	66		7			
Clone > 50%:	Thrombosi	s (pat)	Pat yrs	Per 100 patient yrs		
Before Warfarin	19		511.5	3.7		
On Warfarin:	0		117.8	0		
10 yr cumulative t	hrombosis in	cidence	clone >50 <i>vs</i> < 50%			
	All			34.5 : 5.3%		
I	Not on antico	agulation	44.0 : 5.8%			

EVIDENCE: Moderate

2 serious haemorrhages in 117.8 patient yrs on anti-coagulation. Petra Muus

04/10/2024

Prevention: No anticoagulation in PNH

Incidence of thrombosis ? No anticoagulation??

All of France

Socie G. et al Lancet 1996; 348: 573-577
220 patients 1950-1995: 8 yrs 28%
Loschi *et al* AJH 2016; 91:366-370. 9.4 yrs 27%
Historical controls 191 PNH patients with indication for eculizumab before this was available.

Hammersmith Hospital London

• Hillmen *et al* 1995: 80 Pat.1940 - 1970

10 yrs39%Not enough info for GRADE evidence

Prevention

Cascade of thromboses progressing during sequentially fenprocoumon, nadroparine, danaparoid, aspirin, stopped with eculizumab.

Schutgens et al : Thrombosis and Haemostasis 2011; 106(2) 383-385

F age 43 :

- **PE** (1991) : NSAA and HAM +: PNH. Haemolysis since 1993. Anticoagulation 1993 - 1998. No other treatment.
- **DVT** (2003): LDH 7.5x ULN Hb 60 g/L, reticulocytes 247x10.9/L, 90% PNH granulocytes. Anticoagulation. Transfusions 3x/yr.
- Skin thrombosis (2009): Complement activating event: Parvo B19 infection.

Cascade of thromboses, continued:

Day 1: Fever, arthralgia

Day 2: Purpura skin over wide expanding area, day 6 biopsy LDH 4xULN, Hb 70 g/L, Plt 48x10.9/L

Day 14: ACS: distal occlusion right Coronary Art.

Percutaneous coronary intervention: stenting, acetyl salicylic acid, clopidrogel, aggrastat (GPIIb/IIIa receptor antagonist).

Day 18: ACS distal occlusion left Coronary Art and complete occlusion of the right Coronary Art (not in stent)

Inaccessible for intervention. GPIIb/IIIa receptor antagonist

Day 19: commencement of eculizumab. End of thrombosis cascade. She is well since. Scars from deep skin thrombosis.

Rash since a few hrs in untreated PNH pat on vit K antagonist Otters *et al*, Br J Dermatology, 2013



Prevention

Conclusion of PICO question: benefit from anticoagulation in untreated patients: maybe?

- Preventive anticoagulation did not prevent multiple thrombotic events.
- Multiple thromboses, both years apart and as a cascade within months in same patient.
- Parvo virus was the CAC leading to skin- and further thromboses
- C5 inhibition best option to stop thromboses

GRADE Evidence: moderate at best

Discussion:

More serious even if no anticoagulation?

Thrombosis different if single event *versus* cascade?

Prevention of thrombosis with eculizumab: yes or no

Yes

Loschi *et al* AJH 2016:91:366-370: 123 patients eculizumab vs 191 historical controls

No preventive anticoagulation used in France.

Follow-up

- 4.5 (2.5 5.6) yrs for the eculizumab group
- 9.4 (2.2 15.9) yrs for the control group

4% TE = 5 patients 27% TE

Prevention of thrombosis with eculizumab, and with ravulizumab? yes

Major studies:

Ecu: Hillmen *et al,* 2007

Ecu: Hillmen et al, 2013

Rav: Kulasekararaj et al, 2022**

Ecu/Rav, 20 yrs: Kelly et al, 2024

Ecu/Rav, Gumari et al, 2024

Thrombosis incidence

1.07 vs 7.37 /100 pat yrs

2.1 vs 7.37 /100 pat yrs

1.21/100 pat yrs

0.73/100 pat yrs

2.1 /100 pat yrs

Note: TE considered: TEAE. Better to study freedom of TE as endpoint.

GRADE evidence: high

Prevention of thrombosis with early inhibitor Pegcetacoplan? yes or no?

Kelly et al: Res Pract Thromb Haemost. 2024 May; 8(4): 102416.

Yes

Retrospective study all clinical trials and postmarketing experience 464 patients 619.4 pat yrs 7 thrombotic events in 6 patients, 5/7 in the trials and 2/7 post marketing.

TE: 1.13 per 100 patient yrs

Clinical trials 409.4 pat yrs : 1.22/100 pat yrs Post marketing 210 pat yrs : 0.95/100 pat yrs

Note: Pegasus patients previously on C5 inhbitors and anticoagulation likely stopped then.

GRADE evidence moderate /high

Prevention of thrombosis in other early inhibitors: No studies.

Unknown:

- Crovalimab
- Iptacopan
- Danicopan
- Others.

Prevention anticoagulation during C5 inhibition: yes or no

Yes: if no contra-indication

- Pregnancy and <u>></u> 3 months until end of breast feeding (eculizumab and LMWH).
 GRADE evidence? HIGH
- Prior thrombosis. **GRADE evidence? MODERATE**

Pregnancies before eculizumab: despite LMWH

- Maternal mortality 8 and 20.8% by thrombo embolism, post-partum.
- Fetal mortality 4 and 9% due to premature births

De Guibert *et al: Haematologica* 2011;96:1276-1283

Prevention

LMWH + Eculizumab in pregnancy + 3 months /end breast feeding R Kelly et al: NEJM 2015;373:1032-1039

- Retrospective study: 75 pregnancies in 61 women. Prior thrombosis: 8/61
- LMWH at doses:
 - therapeutic 27/66
 - intermed 7/66
 - prophylactic 32/66
- Eculizumab start before conception (n=46), or in 2nd or 3rd trimester (29).
- Outcome:
 - Thrombosis : None during pregnancy, 2 post-partum and 2 more after stopping eculizumab postpartum, one during ongoing LMWH anticoagulation.

But: 10 haemorhages in patients on LMWH in therapeutic (n=2) or prophylactic dose (n=7) or no anticoagulation.

Prevention

Primary anticoagulation during stable complement inhibition, yes or no?

Νο

 Eculizumab: Hillmen <i>et al</i>, 2007 	1.07/100 pat yrs
 Ravulizumab: Kulasekararaj et al, 2022 	1.21/100 pat yrs
 C5 inhibitors, 20 yrs: Kelly et al, 2024 	0.73/100 pat yrs
 C5 inhibitors, Gumari et al, 2024 	2.1 /100 pat yrs
 Crovalimab 2024 	?
 Pegcetacoplan: Kelly <i>et al</i>, 2024: 	? 1.13/100 pat yrs
 Add on Danicopan 	!

GRADE evidence : high for ecu/rav and likely add on danicopan
Moderate for pegcetacoplan
Unknown for Crovalimab, Iptacopan and others:

Re-commence anticoagulation during complement inhibition at Complement Amplifying Conditions (CAC) and/or Breakthrough Haemolysis: yes or no?

From:

- Brodsky et al Haematologica 2021; 106 (1): 230-237: Substudy into causes of BTH in Phase III randomized studies of ravulizumab vs eculizumab (trials 301 and 302).
- Dingli et al Hematology 2024; 29: No1, 2329030, expert consensus on pharmacodynamic BTH

Outcome unknown. No known studies.

Common practise: Treat the CAC and the BTH

Discussion: Would anticoagulation "make up" for insufficient inhibition of complement?

TREATMENT of Thrombosis

Role of thrombolysis /intervention in Thrombosis in PNH: yes or no.

YES

• Araten et al, 2012, Haematologica: Thrombolysis 9 pat cases + lit rev.

Severe cases up to 6 weeks after first symptoms and worsening despite anticoagulation.

- Percutaneous transluminal angioplasty or TIPS when patient presents with Splanchnic Vein Thrombosis (SVT). Elkrief et al, 2023, vol 5 100667. review .
- Stroke or Myocardial infarction: BMJ trial comparing intra thrombus thrombolysis and aspiration thrombectomy: ongoing. MBJ Open 2023 13(11) e076476.

GRADE evidence: Moderate

D Araten et al, Haematologica 2012. 2012;97(3): 344-352Pat 2, 8 and 9 on anticoagulation prior to thrombotic event.Table 1B1985-2009: reported 15 pat: tPA (6),Urokinase (6), Streptokinase (3)

Patients who received thrombolytic therapy: clinical course.

Pt	Presentation of thrombotic episode	Sites of thrombosis	Estimated onset before tPA	Total n. of courses of tPA	N. of admissions for tPA	Sites of hemorrhage	Initial radiologic response		Eventual outcome ^e	Current status	N. of 1 follo
1	Massive ascites, deep jaundice	HV, PV, IVC, SV	6 wks	5	1	Flank	PR	Warfarin	CR	Excellent	4.5
2	Abd pain and HA	PV, SV, IVC, HV, SS	1 wks	3	2	None	CR	LMWH→ fondaparinux, eculizumab	CR	Excellent	7.5
3	Abd pain	PV, HV	4 wks	2	1	Subcutaneous	nCR	Warfarin, eculizumab	nCR	Excellent	7
4	Vomiting, distention jaundice	TVS, JV, IVC, RV, HV, SMV	2 wks	3	1	SDH	nCR	NA	Died	Died	-
5	Renal failure	RV, JV, IVC, SCV	Few wks	2	1	Vaginal bleedinç	g Impr	Warfarin, LMWH, eculizumab	nCR	Excellent	13
6	Abd pain	HV	Few wks	3.5	1 5	SDH, mesenteri	c PR	NA	CR°, Died	Died	**
7	Abd pain	HV	Few wks	1.5	3	Pleural effusion epistaxis	, CR	Fondaparinux, eculizumab	Partial Budd Chiari	Excellent	4
8	Budd-Chiari	IVC, HV	Few days	4	4	CNS	PR	LMWH [#] eculizumab	Recurrent relapses	Good	4
9	Budd-Chiari	PV, HV	1 month	3	1	Psoas muscle	PR	Fondaparinux, eculizumab	PR	Died	1

Abd: abdominal; uvks: weeks; HV: hepatic vein; PV: portal vein; SV: splenic vein; JV: jugular vein; SMV: superior mesenteric vein; RV: renal vein; TVS: transverse sinus; SS: sagittal sinus; SCV: subclavian vein; CR: complete resolution; PR: partial resolution; nCR: near complete resolution; Impr: improvement; SDH: subdural hematoma; LMWH: low molecular weight heparin; HA: headache. "Fotal number of 24 h infusions administered during initial presentation; "initial response during first hospitalization; "eventual radiologic outcome of initial thrombosis; "years of clinical follow-up after the initial tPA infusion, "patent on post-mortem examination 'elevated WBC, progression to chronic neutrophilic leukemia associated with acquired JAK2 mutation, treatment with decitabine, iron overload; "LMWH was discontinued after his bleeding complications, and he has been stable on eculizumab since then.

Petra Muus

Treatment of thrombosis: Prompt eculizumab: yes or no

• Yes: GRADE evidence: high

Discussion: prompt= same or next day, or within n weeks.

Discussion

- Same day commencement eculizumab if thrombosis
- If C5 inhibitor is available, could suction /thrombolyse/stenting be omitted in MI, Splanchnic Vein Thrombosis or Stroke
- Continue anticoagulation in stable early complement inhibition / newer C5 inhibition.
- How to study "freedom of thrombosis" as an "endpoint" in complement inhibitor studies.
- Cascade of thromboses and isolated thrombosis: different pathophysiology?